Profil
Takeshi Takahashi is currently the Director at Pathalys Pharma, Inc. He previously worked as an Independent Director at Mineralys Therapeutics, Inc. from 2020 to 2023.
He also held the position of Co-Chief Operating Officer & Manager-Technology II at Tsugami Corp.
Mr. Takahashi completed his undergraduate degree at Waseda University and holds an MBA from Kellogg School of Management.
Aktiva positioner av Takeshi Takahashi
| Företag | Position | Start |
|---|---|---|
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. BiotechnologyHealth Technology Operates as late-stage clinical biopharmaceutical company that develops therapeutics for chronic kidney disease | Direktör/Styrelseledamot | - |
Tidigare kända positioner av Takeshi Takahashi
| Företag | Position | Slut |
|---|---|---|
| MINERALYS THERAPEUTICS, INC. | Direktör/Styrelseledamot | 2023-09-12 |
| TSUGAMI CORPORATION | Verksamhetschef | - |
Takeshi Takahashis utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
Tsugami Corp.
Tsugami Corp. Industrial MachineryProducer Manufacturing Engages in the manufacture and sale of precision machine tools | Producer Manufacturing |
Waseda University
Waseda University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kellogg School of Management
Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops medicines to target diseases | Health Technology |
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. BiotechnologyHealth Technology Operates as late-stage clinical biopharmaceutical company that develops therapeutics for chronic kidney disease | Health Technology |
















